Studies of Mild Cognitive Decline and AD patients using short-term intra-nasal insulin (4 months or less) showed significantly less decline in cognition as measured by Voice Onset Time, Delayed Story Recall Score, the Dementia Rating Severity Scale and the ADCS-ADL scale as compared to the placebo group (Reger et al. 2008). This evidence concerns the gene INS and Alzheimer disease.